© 2002 European Society of Cardiology
Glucose insulin potassium infusion improves systolic function in patients with chronic ischemic cardiomyopathy
a Cardiology Department University Hospital, Dijon, France
b Anesthesiology Department University Hospital, Dijon, France
c LPPCE, Faculty of Medicine University of Burgundy, Dijon, France
* Corresponding author. Service de Cardiologie, Hôpital du Bocage, Bd de lattre de Tassigny, 21034 Dijon, Cedex, France. Tel.: +33-3-80293311; fax: +33-3-80293333. E-mail address: yves.cottin{at}chu-dijon.fr
 |
Abstract |
|---|
Objective: We assessed the effects of glucose–insulin–potassium (GIK) by echocardiography in stable patients with ischemic dysfunction.
Methods: Twelve male patients with stable coronary disease (SCD) and ejection fraction (EF) <45% were studied for systolic function. GIK (glucose 30%, 300 insulin units and KCl 6 g/l) was infused at 1 ml/kg per h over 20 min. Hemodynamic and echocardiographic measurements were recorded at rest (T0), at the end (20 min) of GIK infusion (T + 20), 20 and 40 min after the end of the infusion (T + 40 and T + 60).
Results: At T + 20, a significant decrease in WMSI (wall motion score index) was observed compared with T0 (2.16±0.14 vs. 2.30±0.16: P<0.05). An increase in EF was reported at T + 40 and T + 60 compared with T0 (44.1±7.8% and 53.3±11.6% vs. 35.6±4.5%, respectively: P<0.01). A decrease in WMSI was observed at T + 40 and T + 60 compared with rest (2.02±0.17 and 1.93±0.11 vs. 2.30±0.16, respectively: P<0.01).
Conclusion: Our present work suggests that GIK infusion improves systolic function in patients with SCD and ejection fraction <45%. Further studies are needed to determine if short-term GIK infusion could be useful for therapeutic or diagnostic strategies in these patients.
Key Words: Glucose–insulin–potassium • Echocardiography • Left ventricular function
Received January 10, 2001; Revised May 8, 2001; Accepted August 14, 2001
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. Ashrafian, M. P. Frenneaux, and L. H. Opie Metabolic Mechanisms in Heart Failure Circulation, July 24, 2007; 116(4): 434 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Lopaschuk Optimizing cardiac Fatty Acid and glucose metabolism as an approach to treating heart failure. Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2006; 10(3): 228 - 230. [Abstract] [PDF]
|
|
|
|
 |
|
 W. C. Stanley, F. A. Recchia, and G. D. Lopaschuk Myocardial Substrate Metabolism in the Normal and Failing Heart Physiol Rev, July 1, 2005; 85(3): 1093 - 1129. [Abstract] [Full Text] [PDF]
|
|